Cargando…
PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616354/ http://dx.doi.org/10.1093/ijnp/pyw041.419 |
| _version_ | 1783266762282762240 |
|---|---|
| author | Savitz, A Gopal, S Xu, H Zhuo, J Yu, L Nuamah, I Wu, C Hough, D Mathews, M. Feng, Y |
| author_facet | Savitz, A Gopal, S Xu, H Zhuo, J Yu, L Nuamah, I Wu, C Hough, D Mathews, M. Feng, Y |
| author_sort | Savitz, A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5616354 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56163542017-11-27 PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study Savitz, A Gopal, S Xu, H Zhuo, J Yu, L Nuamah, I Wu, C Hough, D Mathews, M. Feng, Y Int J Neuropsychopharmacol Abstracts Oxford University Press 2016-05-27 /pmc/articles/PMC5616354/ http://dx.doi.org/10.1093/ijnp/pyw041.419 Text en © The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. |
| spellingShingle | Abstracts Savitz, A Gopal, S Xu, H Zhuo, J Yu, L Nuamah, I Wu, C Hough, D Mathews, M. Feng, Y PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study |
| title | PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study |
| title_full | PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study |
| title_fullStr | PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study |
| title_full_unstemmed | PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study |
| title_short | PM419. Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study |
| title_sort | pm419. efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in asian patients with schizophrenia: subgroup analysis of a randomized, double-blind, noninferiority study |
| topic | Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5616354/ http://dx.doi.org/10.1093/ijnp/pyw041.419 |
| work_keys_str_mv | AT savitza pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT gopals pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT xuh pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT zhuoj pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT yul pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT nuamahi pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT wuc pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT houghd pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT mathewsm pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy AT fengy pm419efficacyandsafetyofpaliperidonepalmitate3monthlyversus1monthlyformulationinasianpatientswithschizophreniasubgroupanalysisofarandomizeddoubleblindnoninferioritystudy |